50 Participants Needed

Remote Monitoring for Bladder Cancer

(WATCH Trial)

KM
BJ
Overseen ByBruce Jacobs, MD, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Pittsburgh
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

Following radical cystectomy for bladder cancer, nearly two-thirds of patients experience a complication and almost a third are readmitted. Thus, intensified monitoring of this vulnerable group represents an opportunity for improved quality of care in the post-operative setting. By gathering biomarkers passively and continuously, wearable activity monitors augment remote patient monitoring. Further, they facilitate the collection of patient-reported outcomes frequently. Despite the proven impact of remote monitoring on patient care, there is limited data on the feasibility and impact of employing this technology to trigger real-time provider assessment following cystectomy. The investigators plan to conduct a randomized control trial examining such. The intervention group of participants will receive continuous biomarker monitoring via FitBits and daily patient-reported outcome assessments via connected smartphones. Abnormalities in remote data will trigger automated alerts to providers. Providers will respond in real-time to these alerts and patients will receive education materials discussing preventative measures to mitigate the main risk factors for readmissions. The investigators will evaluate the feasibility of integrating this technology into the post-operative period, as well as the impact of real-time provider attention to abnormal remote data on patient-reported outcomes and rates of readmission. The investigators hypothesize that early assessment of and intervention on remote abnormalities will promote the use of outpatient or reduced intensity therapies, such as oral antibiotics or oral hydration, thus curtailing the severity of patient symptoms, intensity of complications, and need for hospitalizations. Ultimately, this trial builds upon prior research, applying patient-centered technology to improve the quality of care following cystectomy.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Remote Monitoring for Bladder Cancer?

Research shows that remote patient monitoring, which involves tracking health data from patients at home, can help manage symptoms and improve recovery in cancer patients undergoing surgery. This approach has been found useful in other types of cancer care, suggesting it could be beneficial for bladder cancer as well.12345

How is the Remote Monitoring treatment for bladder cancer different from other treatments?

Remote Monitoring for bladder cancer is unique because it uses technology to track a patient's health from a distance, allowing for continuous observation without frequent hospital visits. This approach is different from traditional treatments like surgery or radiation, which require direct medical intervention.678910

Research Team

KM

Kathryn Marchetti, MD

Principal Investigator

University of Pittsburgh Medical Center

Eligibility Criteria

This trial is for English-speaking individuals who are undergoing cystectomy at a single center and own a smartphone. It's not open to those unwilling or unable to participate, non-English speakers, or those without a smartphone.

Inclusion Criteria

English speaking
Owns smart phone
I am scheduled for bladder removal surgery at one hospital.

Exclusion Criteria

Does not own smart phone
I am willing and able to participate in the trial.
Non-English speaking

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Post-operative Monitoring

Participants receive continuous biomarker monitoring via FitBits and daily patient-reported outcome assessments via connected smartphones. Abnormalities trigger automated alerts to providers.

4 weeks
Continuous remote monitoring

Follow-up

Participants are monitored for safety and effectiveness after the post-operative monitoring period

4 weeks

Treatment Details

Interventions

  • Remote Monitoring
Trial Overview The study tests if remote monitoring with FitBits and smartphones can improve care after bladder cancer surgery. Participants will be randomly assigned to either get continuous biomarker monitoring and daily health reports, with provider alerts for any issues, or standard post-operative care.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: remote monitoring without provider feedbackExperimental Treatment1 Intervention
remote monitoring with FitBit device and daily patient-reported outcome assessment, without real-time provider feedback
Group II: remote monitoring with provider feedbackExperimental Treatment2 Interventions
remote monitoring with FitBit device and daily patient-reported outcome assessment, as well as real-time provider feedback in response to remote data

Remote Monitoring is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Remote Monitoring for:
  • Cardiac Implantable Electronic Devices (CIEDs) management
  • Implantable Cardioverter Defibrillator (ICD) monitoring
  • Pacemaker (PM) surveillance
🇺🇸
Approved in United States as Remote Monitoring for:
  • CIEDs management
  • ICD monitoring
  • PM surveillance
🇨🇦
Approved in Canada as Remote Monitoring for:
  • CIEDs management
  • ICD monitoring
  • PM surveillance (limited use)

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Pittsburgh

Lead Sponsor

Trials
1,820
Recruited
16,360,000+

Findings from Research

Remote patient monitoring using patient-generated health data can help assess and improve recovery for cancer patients undergoing complex urologic and gynecologic surgeries.
This integrative review highlights the potential benefits of remote monitoring in addressing postoperative symptoms and functional declines, although specific data on the effectiveness and implementation are not detailed in the abstract.
Integrative review of remote patient monitoring in gynecologic and urologic surgical oncology.Perez, F., Nolde, M., Crane, TE., et al.[2023]
A study involving 21 complex general and urologic oncology surgery patients showed that remote telemonitoring of health data and patient-reported outcomes is feasible, with high adherence rates of 95% before surgery and 91% at discharge.
Despite high adherence, patients experienced significant declines in mobility and daily activities shortly after discharge, indicating the need for ongoing support and monitoring in recovery.
Feasibility of perioperative remote monitoring of patient-generated health data in complex surgical oncology.Melstrom, LG., Zhou, X., Kaiser, A., et al.[2023]
Remote patient monitoring software (RPMS) in oncology care significantly improves health-related quality of life and reduces physical symptom burden during cancer treatment, based on a review of nine randomized controlled trials.
The effectiveness of RPMS is enhanced when integrated into routine clinical care, particularly with nurses involved in remote monitoring, indicating that this model can be a valuable addition to standard cancer care practices.
Effects of Patient-Reported Outcome Tracking and Health Information Provision via Remote Patient Monitoring Software on Patient Outcomes in Oncology Care: A Systematic Review and Meta-Analysis.Wang, T., Ho, MH., Tong, MCF., et al.[2023]

References

Integrative review of remote patient monitoring in gynecologic and urologic surgical oncology. [2023]
Feasibility of perioperative remote monitoring of patient-generated health data in complex surgical oncology. [2023]
Effects of Patient-Reported Outcome Tracking and Health Information Provision via Remote Patient Monitoring Software on Patient Outcomes in Oncology Care: A Systematic Review and Meta-Analysis. [2023]
Active surveillance of chemotherapy-related symptom burden in ambulatory cancer patients via the implementation of electronic patient-reported outcomes and sensor-enabled vital signs capture: protocol for a decentralised feasibility pilot study. [2022]
Remote System for Daily Symptom Monitoring During Systemic Anticancer Treatment: Patient Acceptance, Usability, and Compliance. [2022]
Robotic-assisted radical cystectomy. [2008]
Radiation therapy outcomes in muscle invasive urinary bladder cancer: A single institution experience. [2017]
Long-term outcomes of robot-assisted radical cystectomy for bladder cancer. [2022]
Novel multisensor probe for monitoring bladder temperature during locoregional chemohyperthermia for nonmuscle-invasive bladder cancer: technical feasibility study. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Robotic radical cystectomy: where are we today, where will we be tomorrow? [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security